Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Safety Extension Study With Benralizumab for Asthmatic Adults on Inhaled Corticosteroid Plus Long-acting β2 Agonist (MELTEMI)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02808819
Recruitment Status : Active, not recruiting
First Posted : June 22, 2016
Last Update Posted : May 14, 2019
Sponsor:
Information provided by (Responsible Party):
AstraZeneca

Brief Summary:
The purpose of this study is to continue to characterize the safety profile of benralizumab administration and monitor the pharmacodynamic activity of the drug in those asthma patients who remain on treatment for at least 16 weeks and not more than 40 weeks in the predecessor study D3250C00021 (BORA).

Condition or disease Intervention/treatment Phase
Asthma Biological: Benralizumab Phase 3

Detailed Description:
This is an open-label safety extension study designed to evaluate the safety and tolerability of a fixed 30 mg dose of benralizumab administered subcutaneously (SC) in severe asthma patients on inhaled corticosteroid and long-acting β2 agonist (ICS-LABA) therapy with or without chronic oral corticosteroids (OCS) and/or other asthma controllers. All patients will receive active drug on the same dosing regimen they received in BORA. In order to protect the blind of BORA, patients will remain blinded to treatment regimen allocation until they have completed all end of treatment (EOT) assessments in BORA and signed informed consent for participation in this study, after which treatment allocation will be unblinded to both the investigator and the patient.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 446 participants
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Other
Official Title: A Multicenter, Open-label, Safety Extension Study With Benralizumab (MEDI-563) for Asthmatic Adults on Inhaled Corticosteroid Plus Long-acting β2 Agonist (MELTEMI)
Actual Study Start Date : June 30, 2016
Estimated Primary Completion Date : June 29, 2020
Estimated Study Completion Date : June 29, 2020

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Asthma

Arm Intervention/treatment
Benralizumab Arm A
Benralizumab administered subcutaneously every 4 weeks
Biological: Benralizumab
Benralizumab administered subcutaneously every 4 weeks

Benralizumab Arm B
Benralizumab administered subcutaneously every 8 weeks
Biological: Benralizumab
Benralizumab administered subcutaneously every 8 weeks




Primary Outcome Measures :
  1. Number of subjects with Adverse Events or Serious Adverse Events (AEs/SAEs) [ Time Frame: From week 0 to week 130 in the study treatment period and through the follow up period (12 weeks after last dose) ]
    Number of Adverse Events/ Serious Adverse Events

  2. Shift from baseline to maximum post-baseline in standard chemistry lab parameters [ Time Frame: Up to week 130 in the study treatment period and through the follow up period (12 weeks after last dose) ]
  3. Shift from baseline to minimum post-baseline in standard chemistry lab parameters [ Time Frame: Up to week 130 in the study treatment period and through the follow up period (12 weeks after last dose) ]
  4. Shift from baseline to maximum post-baseline in standard hematology lab parameters [ Time Frame: Up to week 130 in the study treatment period and through the follow up period (12 weeks after last dose) ]
  5. Shift from baseline to minimum post-baseline in standard hematology lab parameters [ Time Frame: Up to week 130 in the study treatment period and through the follow up period (12 weeks after last dose) ]

Secondary Outcome Measures :
  1. Number of asthma exacerbations [ Time Frame: Up to week 130 in the study treatment period and through the follow up period (12 weeks after last dose) ]
    Annual asthma exacerbation rate

  2. Number of exacerbations requiring hospitalization [ Time Frame: Up to week 130 in the study treatment period and through the follow up period (12 weeks after last dose) ]
    Annual exacerbations rate requiring hospitalization

  3. Number of exacerbations requiring emergency room visit [ Time Frame: Up to week 130 in the study treatment period and through the follow up period (12 weeks after last dose) ]
    Annual exacerbations rate requiring emergency room visit

  4. Absolute eosinophil counts [ Time Frame: Every 16 weeks for the first year and every 24 weeks after first year up to week 130 in the study treatment period and through the follow up period (12 weeks after last dose) ]
  5. Anti-drug antibodies (ADA) as a measure of immunogenicity [ Time Frame: Every 16 weeks for the first year and every 24 weeks after first year up to week 130 in the study treatment period and through the follow up period (12 weeks after last dose) ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 130 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Informed consent for study participation must be obtained prior to any study related procedures being performed and according to international guidelines and/or applicable European Union guidelines.
  • Female and male patients who have completed at least 16 and not more than 40 weeks in Study D3250C00021.
  • Women of childbearing potential (WOCBP) must agree to use an effective form of birth control throughout the study duration and for 16 weeks after the last dose of Investigational Product (IP)
  • For WOCBP only: Have a negative urine pregnancy test prior to administration of IP at Visit 1.
  • All male patients who are sexually active must agree to use a double barrier method of contraception (condom with spermicide) from the first dose of IP until 16 weeks after their last dose.

Exclusion Criteria:

  • Any disorder including but not limited to cardiovascular, gastrointestinal, hepatic, renal, neurological, musculoskeletal, infectious, endocrine, metabolic, hematological, psychiatric or major physical impairment that is not stable in the opinion of the Investigator and could:

    • Affect the safety of the patient throughout the study
    • Influence the findings of the study or their interpretations
    • Impede the patient's ability to complete the entire duration of study
  • A helminth parasitic infection diagnosed during a predecessor study that has either required hospitalization, has not been treated, has been incompletely treated or has failed to respond to standard of care therapy
  • Any clinically significant change in physical examination, vital signs, ECG, hematology, clinical chemistry, or urinalysis during the predecessor study which in the opinion of the investigator may put the patient at risk because of his/her participation in the study, or may influence the results of the study, or interfere with the patient's ability to complete the entire duration of the study
  • Current malignancy or malignancy that developed during the predecessor study (subjects that had basal cell carcinoma, localized squamous cell carcinoma of the skin which was resected for cure, or in situ carcinoma of the cervix that has been treated/cured will not be excluded).
  • Receipt of live attenuated vaccines within 30 days prior to initiation of treatment in this study, during the treatment period, and for 16 weeks (5 half-lives) after the last dose of the IP
  • Receipt of immunoglobulin or blood products within 30 days prior to Visit 1
  • Planned major surgical procedures during the conduct of the study
  • Previous participation in the present study
  • Concurrent enrolment in another drug-related interventional clinical trial
  • AstraZeneca staff involved in the planning and/or conduct of the study
  • Employees of the study center or any other individuals involved with the conduct of the study or immediate family members of such individuals
  • Patients with important protocol deviations in the predecessor study at the discretion of the Sponsor
  • Patients with ongoing serious adverse events (SAEs) from the prior study should not be enrolled into the this extension study until the SAE has resolved

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02808819


  Hide Study Locations
Locations
Layout table for location information
United States, Alabama
Research Site
Scottsboro, Alabama, United States, 35768
United States, Arizona
Research Site
Glendale, Arizona, United States, 85306
Research Site
Phoenix, Arizona, United States, 85012
United States, California
Research Site
Bakersfield, California, United States, 93301
Research Site
Newport Beach, California, United States, 92663
Research Site
Redondo Beach, California, United States, 90277
Research Site
Roseville, California, United States, 95661
Research Site
Sacramento, California, United States, 95825
Research Site
San Jose, California, United States, 95117
Research Site
Stockton, California, United States, 95204
Research Site
Westminster, California, United States, 92683
Research Site
Woodland, California, United States, 95695
United States, Colorado
Research Site
Colorado Springs, Colorado, United States, 80907
Research Site
Denver, Colorado, United States, 80206
Research Site
Wheat Ridge, Colorado, United States, 80033
United States, Connecticut
Research Site
New Haven, Connecticut, United States, 06520
United States, Florida
Research Site
Clearwater, Florida, United States, 33765
Research Site
Doral, Florida, United States, 33172
Research Site
Hialeah, Florida, United States, 33012
Research Site
Miami, Florida, United States, 33134
Research Site
Miami, Florida, United States, 33144
Research Site
Miami, Florida, United States, 33176
Research Site
Orlando, Florida, United States, 32819
Research Site
Orlando, Florida, United States, 32825
Research Site
Winter Park, Florida, United States, 32789
United States, Iowa
Research Site
Iowa City, Iowa, United States, 52242
United States, Maine
Research Site
Bangor, Maine, United States, 04401
United States, Massachusetts
Research Site
Quincy, Massachusetts, United States, 02169
United States, Michigan
Research Site
Farmington Hills, Michigan, United States, 48334
Research Site
Flint, Michigan, United States, 48504
Research Site
Traverse City, Michigan, United States, 49686
United States, New York
Research Site
Bronx, New York, United States, 10461
Research Site
New York, New York, United States, 10016
United States, North Carolina
Research Site
Durham, North Carolina, United States, 27705
Research Site
Winston-Salem, North Carolina, United States, 27103
United States, Ohio
Research Site
Cincinnati, Ohio, United States, 45231
Research Site
Middleburg Heights, Ohio, United States, 44130
United States, Oklahoma
Research Site
Oklahoma City, Oklahoma, United States, 73103
Research Site
Oklahoma City, Oklahoma, United States, 73120
United States, Pennsylvania
Research Site
Jefferson Hills, Pennsylvania, United States, 15025
Research Site
Philadelphia, Pennsylvania, United States, 19140
United States, South Carolina
Research Site
Hodges, South Carolina, United States, 29653
United States, South Dakota
Research Site
Rapid City, South Dakota, United States, 57702
United States, Texas
Research Site
Dallas, Texas, United States, 75225
Research Site
Dallas, Texas, United States, 75235
Research Site
Houston, Texas, United States, 77058
Research Site
Houston, Texas, United States, 77081
Research Site
Houston, Texas, United States, 77083
Research Site
McKinney, Texas, United States, 75069
United States, Virginia
Research Site
Abingdon, Virginia, United States, 24210
Research Site
Falls Church, Virginia, United States, 22044
United States, Wisconsin
Research Site
Madison, Wisconsin, United States, 53792
Argentina
Research Site
Buenos Aires, Argentina, C1414AIF
Research Site
Ciudad de Buenos Aire, Argentina, C1425DTG
Research Site
La Plata, Argentina, B1902COS
Research Site
Mendoza, Argentina, 5500
Research Site
Mendoza, Argentina, M5500GIP
Australia
Research Site
Frankston, Australia, 3199
Research Site
Nedlands, Australia, 6009
Research Site
Parkville, Australia, 3050
Research Site
Randwick, Australia, 2031
Research Site
Woolloongabba, Australia, 4102
Bulgaria
Research Site
Pazardzhik, Bulgaria, 4400
Research Site
Pernik, Bulgaria, 2300
Research Site
Petrich, Bulgaria, 2850
Research Site
Ruse, Bulgaria, 7002
Research Site
Sliven, Bulgaria, 8800
Research Site
Vratsa, Bulgaria, 3000
Canada, Alberta
Research Site
Calgary, Alberta, Canada, T2N 4Z6
Research Site
Sherwood Park, Alberta, Canada, T8L 0N2
Canada, British Columbia
Research Site
Vancouver, British Columbia, Canada, V5Z 1M9
Canada, Ontario
Research Site
Hamilton, Ontario, Canada, L8N 4A6
Research Site
Ottawa, Ontario, Canada, K1G-6C6
Canada, Quebec
Research Site
Montreal, Quebec, Canada, H2W 1T8
Research Site
Montreal, Quebec, Canada, H4A 3J1
Canada
Research Site
Quebec, Canada, G1G 3Y8
Research Site
Quebec, Canada, G1V 4G5
Chile
Research Site
Quillota, Chile, 2260000
Research Site
Talcahuano, Chile, 4270918
Research Site
Valparaiso, Chile, 2341131
Czechia
Research Site
Karlovy Vary, Czechia, 360 17
Research Site
Plzen, Czechia, 304 60
Research Site
Praha, Czechia, 130 00
Research Site
Rokycany, Czechia, 337 22
France
Research Site
Brest Cedex 2, France, 29609
Research Site
Dijon Cedex, France, 21079
Research Site
Le Kremlin Bicêtre, France, 94275
Research Site
Le Mans Cedex, France, 72037
Research Site
Lyon Cedex 04, France, 69317
Research Site
Marseille Cedex 20, France, 13915
Research Site
Montpellier, France, 34295
Research Site
Paris, France, 75018
Research Site
Pringy Cedex, France, 74374
Research Site
Saint Pierre, France, 97448
Research Site
Strasbourg Cedex, France, 67091
Research Site
Toulouse Cedex 9, France, 31059
Germany
Research Site
Aschaffenburg, Germany, 63739
Research Site
Bamberg, Germany, 96049
Research Site
Berlin, Germany, 10367
Research Site
Frankfurt/Main, Germany, 60389
Research Site
Frankfurt, Germany, 60596
Research Site
Geesthacht, Germany, 21502
Research Site
Grosshansdorf, Germany, 20927
Research Site
Hamburg, Germany, 22299
Research Site
Hannover, Germany, 30625
Research Site
Hannover, Germany, D-30173
Research Site
Leipzig, Germany, 04103
Research Site
Leipzig, Germany, 04207
Research Site
Mainz, Germany, 55131
Research Site
Rüdersdorf, Germany, 15562
Poland
Research Site
Aleksandrów Łódzki, Poland, 95-070
Research Site
Białystok, Poland, 15-430
Research Site
Bydgoszcz, Poland, 85-168
Research Site
Dobre Miasto, Poland, 11-040
Research Site
Gdańsk, Poland, 80-952
Research Site
Gorzów Wlkp, Poland, 66-400
Research Site
Grodzisk Mazowiecki, Poland, 05-825
Research Site
Kościan, Poland, 64-000
Research Site
Kraków, Poland, 31-011
Research Site
Kraków, Poland, 31-033
Research Site
Lubin, Poland, 59-300
Research Site
Lublin, Poland, 20-552
Research Site
Ostrów Wielkopolski, Poland, 63-400
Research Site
Poznań, Poland, 60-685
Research Site
Poznań, Poland, 60-693
Research Site
Poznań, Poland, 60-823
Research Site
Proszowice, Poland, 32-100
Research Site
Ruda Slaska, Poland, 41-709
Research Site
Rzeszów, Poland, 35-205
Research Site
Skierniewice, Poland, 96-100
Research Site
Sosnowiec, Poland, 41-200
Research Site
Tarnów, Poland, 33-100
Research Site
Trzebnica, Poland, 55-100
Research Site
Warszawa, Poland, 01-138
Research Site
Warszawa, Poland, 01-868
Research Site
Wieluń, Poland, 98-300
Research Site
Wołomin, Poland, 05-200
Research Site
Wrocław, Poland, 50-220
Research Site
Wrocław, Poland, 51-162
Research Site
Wrocław, Poland, 53-301
Research Site
Łódź, Poland, 90-141
Research Site
Łódź, Poland, 91-103
Research Site
Żnin, Poland, 88-400
Russian Federation
Research Site
Ekaterinburg, Russian Federation, 620039
Research Site
Nizhny Novgorod, Russian Federation, 603126
Research Site
Saratov, Russian Federation, 410053
Research Site
Smolensk, Russian Federation, 214019
Research Site
St. Petersburg, Russian Federation, 196247
Research Site
Vladikavkaz, Russian Federation, 362007
Research Site
Volgograd, Russian Federation, 400001
Research Site
Volgograd, Russian Federation, 400131
Research Site
Yekaterinburg, Russian Federation, 620149
Spain
Research Site
Málaga, Spain, 29010
Research Site
Palma de Mallorca, Spain, 07010
Research Site
Sagunto(Valencia), Spain, 46520
Research Site
Salamanca, Spain, 37007
Research Site
Valencia, Spain, 46015
Research Site
Valencia, Spain, 46017
Turkey
Research Site
Adana, Turkey, 01330
Research Site
Ankara, Turkey, 06230
Research Site
Bursa, Turkey, 16059
Research Site
Istanbul, Turkey, 34098
Ukraine
Research Site
Dnipropetrovsk, Ukraine, 49006
Research Site
Ivano-Frankivsk, Ukraine, 76012
Research Site
Kharkiv, Ukraine, 61022
Research Site
Kharkiv, Ukraine, 61035
Research Site
Kharkiv, Ukraine, 61039
Research Site
Kharkiv, Ukraine, 61058
Research Site
Kyiv, Ukraine, 03680
Research Site
Kyiv, Ukraine, 04201
Research Site
Lutsk, Ukraine, 43000
Research Site
Vinnytsia, Ukraine, 21029
United Kingdom
Research Site
Birmingham, United Kingdom, B9 5SS
Research Site
Cambridge, United Kingdom, CB2 0QQ
Research Site
Chertsey, United Kingdom, B9 5SS
Research Site
Cottingham, United Kingdom, HU16 5JQ
Research Site
Nottingham, United Kingdom, NG5 1PB
Research Site
Stevenage, United Kingdom, SG1 4AB
Sponsors and Collaborators
AstraZeneca

Layout table for additonal information
Responsible Party: AstraZeneca
ClinicalTrials.gov Identifier: NCT02808819     History of Changes
Other Study ID Numbers: D3250C00037
First Posted: June 22, 2016    Key Record Dates
Last Update Posted: May 14, 2019
Last Verified: May 2019

Keywords provided by AstraZeneca:
Asthma
Bronchial Diseases
Respiratory Tract Diseases
Lung Diseases
Obstructive Lung Diseases

Additional relevant MeSH terms:
Layout table for MeSH terms
Benralizumab
Anti-Asthmatic Agents
Respiratory System Agents